BACKGROUND: Following the enactment of legislation in June 2013, generic substitution and reference pricing of medicines has been introduced, for the first time, in Ireland. This novel study is the first assessment of the perceptions of community pharmacists in Ireland towards generic medicines completed in the period immediately prior to the introduction of generic substitution and reference pricing.
I
n June 2013, new legislation came into effect in Ireland 1 -the Health (Pricing and Supply of Medical Goods) Act 2013) 2 -that introduced generic substitution and reference pricing for the first time in this country. As a result of this new legislation, Irish patients will now have a greater opportunity to receive a generic medicine instead of a brand-name prescription medication. In an effort to ensure that this legislation is successful, pharmacists' opinions of, and attitudes towards, generic medicines are critical to the changes being implemented-that is, to increase the use of generic medicines in Ireland.
Attitudes of Irish pharmacists towards generics have not been published in the past. While assessments of pharmacist perceptions of generic medicines have been carried out in a limited number of other countries, a PubMed search covering the period from January 2003 to January 2014 did not return any peer-reviewed publications on the topic of pharmacist perceptions of generic medicines in Ireland. In fact, only 10 publications since 2003 were found in PubMed on the topic of pharmacist perceptions of, and attitudes towards, generic 
What is already known about this subject
• This is the first study of pharmacist perceptions of generic medicines in Ireland and 1 of only 6 other studies on pharmacist perceptions of generics in Europe.
• This is only the second qualitative investigation of pharmacist views in Europe-the other being from Sweden and published in 2012.
• This study adds to the body of knowledge on pharmacist attitudes towards generics, providing in-depth, qualitative data that can be used as a basis for policy implementation and decision making.
one interviews were carried out with consenting pharmacists between June and October 2012: 34 face to face and 10 via telephone. Interview lengths were as follows: minimum 10 minutes 44 seconds; maximum 36 minutes and 15 seconds; mean 19 minutes 29 seconds. Interviews that were recorded (with the interviewee's consent) were semistructured and based on the described study instrument (see Table 1 ). Additional supporting assessment of opinions was completed using a series of structured questions to which participants could select from predefined answers ( Table 2) . In this instance, a 5-point Likert scale was used with a single response allowed for each question. 15 Participants were free to volunteer additional commentary on each question. Furthermore, participants were offered the opportunity to express freely any additional opinions or views at the end of the interview session. Participating pharmacists were located in counties Limerick, Tipperary, Kilkenny, Cork, and Waterford. medicines, indicating that this is a relatively underexplored area internationally. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] With Ireland on the cusp of a major modification in health care practices, there are many potential hurdles to overcome during the introduction of such changes. 13 The attitudes and behaviors of health care professionals towards generic medicines are pivotal to the successful implementation of the new legislation. The objective of this novel study was to assess these perceptions among community pharmacists in Ireland in the time leading up to the enactment of the new legislation and to determine what challenges might arise as a result of these stakeholder opinions.
■■ Methods Preparation of Study Instrument
The study instrument was developed based on a recently published review of the usage of generic medicines and how policy changes to promote the use of generic medicines may affect health care provision 14 and the personal experience of the primary author and study designer (who has over 15 years of quality management and regulatory affairs within the pharmaceutical and biopharmaceutical industry).
Questions for the semistructured interview were prepared and validated by cognitive testing, the purpose of which was to ensure that the test questions were understood as intended. The purpose of the interviews was to elucidate perceptions relating to general opinion and understanding of generic medicines; behaviors towards generic medicines (e.g., dispensing behaviors in the case of community pharmacists); opinions as to the historical poor usage of generics in Ireland; beliefs held as to the quality and efficacy of generics and how these compare with proprietary (that is, brand-name) medicines; and knowledge and opinion of the impending legislative change.
Cognitive testing was performed with 3 individuals who were first asked the questions to be included in the survey, allowed to provide responses, and after responding were asked what their understanding of the questions were. Amendments were made to questions based on responses from all 3 test participants. The responses of these participants to the interview questions were not included in those finally analysed for this study. The interviews used in the study began after cognitive testing had been completed, and the interview questions had been amended.
Sampling, Recruitment, and Interviews
A convenience sample of community pharmacists was recruited, and interviews completed and analysed. Pharmacists were approached in person, while in the pharmacy, and invited to participate in the study. A verbal explanation of the study was provided, and an invitation letter was offered. One-to- 
Analysis of Data
Using a grounded theory approach, 16 interviews were transcribed verbatim and imported into NVivo, version 9 (QSR International, Melbourne, Australia) for analysis. Using an inductive process, transcripts were open coded for themes relating to interviewee opinions, perceptions, and behaviors, including any other emerging themes, and the results were analysed using Nvivo. To facilitate visualization and understanding of the numbers of participants holding the perceptions/behaviors that were coded into specific themes, responses were expressed as a percentage of the total number of participants. Interviews were conducted until saturation of data was observed. Analysis was completed by the primary researcher (SD) and reviewed to ensure reliability and rigor of the analysis by a senior investigator (CD).
The coding framework included (but was not limited to) such themes as opinions regarding safety and efficacy; previous experience with use of generics; personal preferences; beliefs regarding historical usage of generics in Ireland; experiences with patient reports regarding generics; prescribing rationales; personal knowledge of, and attitudes towards, generic medicines; and opinions regarding the proposed legislative changes.
Ongoing analysis of themes emerging from the interviews was carried out as interviews were completed. When 4 to 5 consecutive interviews did not lead to the emergence of any new themes, it was determined that data saturation had been achieved and interviewing was concluded.
■■ Results
Supporting quotations from pharmacists are included in Table  3 , as referenced in the text.
Analyzing Pharmacist Interviews
Forty-four community pharmacists were interviewed. Demographics of the group are available in Table 4 . Participating pharmacists were located in counties Limerick, Tipperary, Cork, and Waterford. Table 2 shows the analysis of opinions regarding quality, efficacy, and safety of generics. The majority of pharmacists (98%) were of the belief that generic medicines are of the same quality as the originator, with 96% holding the view that they are as efficacious as brand-name products. All of the pharmacists interviewed believed that generics are as safe as the originator. A small number (9%), however, were of the opinion that generics are not manufactured to the same quality as originator medicines and were of the view that generic manufacturing is of a poorer standard. The majority of pharmacists (93%) stated that they would take a generic medicine themselves, with a small number (7%) stating that they would prefer to take the originator rather than an equivalent generic, if offered a choice (reference quotations 1-3, Table 3 ). Generic medicines are generally better quality than originator medicines. Generic medicines are manufactured to a poorer quality than originator medicines. 
Opinions Regarding Quality, Efficacy, and Safety of Generics

Supporting Quotations from Pharmacists
Pharmacist Experiences with Patient Complaints Regarding Generic Medicines
Of the 44 pharmacists, 39 (89%) reported receiving patient complaints associated with use of a generic medicine. Of the 5 pharmacists who did not experienced these complaints, 1 pharmacist did not dispense generics. Pharmacists reported that when patients had issues with generics, the main experiences described were that the generics were not as effective or that the patients experienced altered or increased side effects. Twenty-eight pharmacists (64%) expressed an opinion that at least some of the negative experiences reported by patients were not actual, but rather were caused by a nocebo effect (i.e., patients' preconceived ideas as to a perceived substandard nature of generics led to them having negative experiences with generics) rather than an actual issue with the medication (reference quotations 4-6, Table 3 ). Medication types most reported as being problematic included protein pump inhibitors (27%, 12/44), statins (18%, 8/44), inhalers (7%, 3/44), antihypertensives (7%, 3/44), antibiotics (7%, 3/44), antidepressants (5%, 2/44), and analgesics (2%, 1/44).
Conversely, 11 pharmacists (25%) stated that a patient had reported an issue with an originator medicine compared with a generic. In most cases, since the patient had received the generic before the originator medication, pharmacists indicated that, in their opinion, the patient's preference is often for the medicine first encountered and that such issues are more likely to be due to a change having occurred, rather than an actual issue with the medicine (reference quotation 7, Table 3 ).
In the situation where pharmacists received complaints from patients related to use of generic medicine and the patients requested the originator instead, 34 pharmacists (77%) stated that they would accede to the patients' preferences (reference quotations 8-9, Table 3 ). Only 9 pharmacists (21%) stated that they would attempt to educate the patient (reference quotations 10-11, Table 3) .
When asked about the differences between an originator and an equivalent generic, 2 pharmacists (5%) felt that there was no difference. Given that the only requirement for similarity (in terms of ingredients) between an originator product and a generic equivalent is that the same active ingredient be used (excipients may vary) and that generic products are often aesthetically different from the originator, patients can be confused if the differences in appearance and excipient content are not adequately explained to them.
Opinions Regarding Low Historic Usage of Generics
When asked why usage of generics in Ireland has been low in the past, the main reasons given by pharmacists were as follows:
• Lack of generic prescribing (31%, 27/44). The primary reasons given for this opinion were familiarity with trade names on the part of prescribers and their lack of knowledge of the generic names of medicines.
Group Gender Age
Pharmacists N = 44 
Supporting Quotations from Pharmacists (continued)
persons who are unable, without undue financial hardship, to arrange general practitioner, medical, or surgical services. Having a medical card entitles holders and their dependents to a number of free services, including prescription medicines (a dispensing charge applies to prescription medicines). In quarter 4 of 2013 approximately 40% of the Irish population were holders of medical cards. 17 Furthermore, some pharmacists felt that branding of generics should be disallowed because it is contrary to the intent of having generic medication and made it necessary for them to stock multiple "brands" of the same generic medication (reference quotation 22, Table 3 ).
Opinions Regarding New Legislation
All of the pharmacists interviewed were aware of the Irish government's plan to introduce reference pricing and generic substitution in Ireland. When asked about their opinions about the new legislation, 35 pharmacists (80%) indicated that they felt positive about the legislation or were accepting of it. Twentyfour pharmacists (55%) were of the opinion that it made financial sense and was necessary for the country, although 20 pharmacists (46%) expressed concerns and reported that they anticipated issues with its practical implementation (reference quotations 23-24, Table 3 ).
■■ Discussion
According to a PubMed search in January 2014, Irish pharmacists' perceptions of generic medicines have not been studied in the past. Internationally, a limited number of assessments have taken place for such countries as New Zealand, 9 Portugal, 4 South Africa, 5 Malaysia, 8 France, 10 and Sweden 6 that included studies on views held regarding specific medication types, such as antiepileptic drugs 7 and inhalers. 3 Given the major changes currently underway in the Irish health care system (i.e., the introduction for the first time of reference pricing and generic substitution), the opinions and behaviors of this critical stakeholder group have the potential to be pivotal to the success or failure of the changes being implemented.
In contrast to other reports of reticent pharmacist views, 3, 8, 9 this study has shown that Irish pharmacists were generally positive towards, and accepting of, generic medicines, with many holding the view that they are as effective as the originator, with the exception of nonsubstitutable situations-such as with Narrow Therapeutic Index drugs-and that differences in presentation can be a source of problems for some patients. Very few pharmacists expressed reticent opinions, but 1 of the primary concerns, as has been reported elsewhere, 6 was that confusion caused by differing aesthetic presentations of generic medicines has the potential to be problematic for patients.
• Lack of government incentive or pressure for generics usage (50%, 22/44).
• The influence of the pharmaceutical industry (i.e, proprietary manufacturers) in Ireland (41%, 18/44).
• Poor understanding of generics by consumers (41%, 18/44).
• Brand consciousness or loyalty on the part of the consumer, including being used to a particular brand and having poor cost consciousness (39%, 17/44).
• The nonallowance of generic substitution (32%, 14/44).
Pharmacist Perceptions of Quality and Patient Issues with Generic Medicines
Three pharmacists (7%) reported having experienced quality issues with generic medicines. Issues reported included crumbling tablets and having difficulty getting tablets out of blister packs. The pharmacists reported that, in their opinion, these issues affect consumer confidence in generic products (reference quotations 12-13, Table 3 ). Poorer packaging was also mentioned by 4 pharmacists (9%) as being perceived as a negative, and 1 pharmacist (2.3%) stated, anecdotally, that differences between originator and generic packaging can even cause issues for patients (e.g., where an originator brand tablet had the days of the week printed on the foil, serving as a reminder to the patient as to whether that day's medication had been taken or not, but similar printing was not available with the generics). This led to patient preference for the originator medicine (reference quotations 14-15, Table 3 ). Nineteen pharmacists (43.2%) also reported the opinion that patients are sometimes resistant to change and that the different aesthetic presentation of generics can cause confusion and medication errors for some patients, particularly the elderly (reference quotations 20-21, Table 3 ).
Consequently, patient education was seen as a necessary step for wider acceptance of generics, and 15 pharmacists (34%) stated that, in their opinion, patients see generics as being a substandard, or lesser, alternative because they are cheaper, which is described as "own-brand syndrome." Indeed, 16 pharmacists (36%) expressed the opinion that Irish patients hold a significant preference for branded medications (reference quotations 18-19, Table 3 ).
Five pharmacists (11.4%) reported having patients who asked for cheaper generics. This was a minority of cases and tended to be limited to private patients, who, according to the pharmacists, have a better understanding and education regarding generics. Pharmacists additionally made reference to General Medical Services (GMS) patients getting more branded medication than private (i.e., self-paying) patients (reference quotations 20-21, Table 3 ). In Ireland, the GMS, or medical card, scheme is a means-tested scheme available to Additionally, generics manufacturers/licence holders may play a role in improving the opinions of consumers regarding their products. One aspect could be to ensure that packaging is of a standard at least equivalent to that of the originator and, where relevant, to ensure that it provides the same facilities for prompting/reminding of patients to take the medication (e.g., the anecdote where a pharmacist stated that continued use of 1 proprietary brand was due to patient preference for the packaging, as the days of the week were printed on the blister pack foil). An argument can be made for regulators approving generic medicines to require that if patient aids are part of the originator packaging, any generic equivalents must provide similar aids in order to obtain a marketing authorization. Moreover, a theme emerged on the topic of branded generics: while generic substitution makes the issue of pharmacists needing stocks of multiple branded generics moot, (that is, unless a "do not substitute" prescription has been written), pharmacists expressed views that branding of generics should not be permitted as, practical aspects aside, branding of generic medications is not in keeping with the intention of provision of generic medicines. Indeed, a recent report from the Irish Economic and Social Research Institute on the costing of generics in Ireland has shown them to be similar to the original branded medication, thereby not resulting in substantial benefit to either the Irish exchequer or consumer. 18 Since improved consumer confidence in generics was considered to be one of the major hurdles to be overcome in improving use of generics in Ireland (similarly noted in other studies [4] [5] [6] ), the question was posed by pharmacists: How can this information/education be provided in a manner that is easy for patients to access and understand? While 1 pharmacist showed a patient both the originator and generic products side by side to prove their equivalency (in the case of asthma inhalers), the practicality of doing this on a day-to-day, patientto-patient basis is obviously something that busy pharmacists cannot undertake. Provision of educational supports could be facilitated, for example, by use of a novel tool, recently published by our group, based on optimized quality of information and reading ability, for development of websites providing health care information. 19 The resulting availability of easy-toread handouts/pamphlets, websites, or similar sources of information may not only provide consumers with the information to dispel myths about generics and, hence, improve their confidence but may also have the dual effect of making the role of the pharmacist easier during a time of upheaval and change.
While a majority of pharmacists were in favor of the new legislation (with references made to the United Kingdom situation: that no clinical issues linked to a much greater use of generic medicines are seen, thus, the same situation could reasonably be expected in Ireland without risk to patients) about half of the pharmacists interviewed (46%, 20/44) expressed concerns as to the practical implementation of associated changes. Concerns included the impact on the running of the pharmacy as well as on patients. Pharmacists felt that they could meet considerable resistance from patients and that they, being at the "coal face," may need to spend substantial periods of time explaining the new system to patients, if adequate educative interventions are not put in place by either the government or other interested bodies (e.g., the Pharmaceutical Society of Ireland). Indeed, the requirement for education of the general public to improve opinions and, therefore, increase patient acceptance of generics was a recurring theme in this study, as it has been in other studies. [4] [5] [6] 10 Increased public awareness and education were considered to be fundamental to improved acceptance of generics by consumers. In fact, an anecdote told by a pharmacist, regarding how she convinced a patient who was reticent to take a generic version of an inhaler, is indicative of how such an intervention might work. The pharmacist told how she brought out both the generic and the proprietary inhalers and showed both to the patient, pointing out the ingredients of both and showing the patient that they were the same. This practical demonstration of equivalence convinced the patient to try the generic inhaler, and the pharmacist indicated that the patient did not return with any subsequent issues. Such examples should be made use of when designing educational interventions for patients.
Patient preference was seen to have a considerable influence on dispensing practices, with many pharmacists (77%, 34/44) acceding to patients' wishes for brand-name medications, despite the fact that pharmacists believed the majority of issues/complaints from patients regarding generics are not actual, but rather due to the nocebo effect, that is, patients' prejudices regarding generic medicines (reference quotation 25, Table 3 ). Pharmacists were of the opinion that this negative patient perception may be based on the fact that generics are less expensive so, therefore, cannot be as good (reference quotation 26, Table 3 ). Also, pharmacists believed that many negative patient experiences were due to changes in medication and that the first medication that the patient is exposed to will tend to be the preferred option. Therefore, when this is changed, the patient is more likely to experience a problem (reference quotation 27, Table 3 ).
DISCLOSURES
The authors do not have any financial interest, have not received any funding for this study, and do not have any conflicts of interest. This work was supported in part by a scholarship from the Faculty of Education and Health Sciences, University of Limerick, Ireland.
S. Dunne was responsible for study design, data collection, and data interpretation and was primarily responsible for the writing of the manuscript, with assistance from C. Dunne. All authors contributed equally to manuscript revision.
